NCT06757296 Endoscopic Conversion of Sleeve Gastrectomy to Single Anastomosis Sleeve-ileal Bypass (SASI) for Gastroesophageal Reflux (GERD), Primary and Secondary Non-responder.
| NCT ID | NCT06757296 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Singapore Health Services |
| Condition | Metabolic Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-02-03 |
| Primary Completion | 2026-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2025-02-03 with a primary completion date of 2026-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to determine the feasibility and effectiveness of endoscopic anastomosis of sleeve gastrectomy to ileum with a lumen apposing metal stent (LAMS) after a failed sleeve gastrectomy.
Eligibility Criteria
Inclusion Criteria: Subject must meet all the inclusion criteria to participate in this study and list each criterion. 1. Age: 21-65 years 2. Patients going for LSG at participating hospitals. 3. Able to provide informed consent Individuals below age 21 would not be recruited as this is a study in the adult population. Individuals above age 65 are excluded to minimize the procedure risk. Exclusion Criteria: 1. Patients who were breast feeding or pregnant 2. Severe psychiatric illness 3. Eating disorder 4. Active neoplastic disease 5. End-stage renal disease 6. Patients with bleeding diathesis 7. Patients with pacemakers or implantable cardiac defibrillators 8. Significant cardiovascular disease (e.g., acute myocardial infarction, congestive cardiac failure, ischemic heart disease, atrial fibrillation, sick sinus syndrome, supraventricular tachycardia) 9. Any factors likely to limit adherence to study protocol (e.g., dementia; alcohol or substance abuse; history of unreliability in medication taking or appointment keeping; significant concerns about participation in the study from spouse, significant other or family members) 10. Treatment with anti-platelet agents that could not be temporarily discontinued
Contact & Investigator
Chin Hong Lim, MD
PRINCIPAL INVESTIGATOR
Singapore General Hospital
Frequently Asked Questions
Who can join the NCT06757296 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 65 Years, studying Metabolic Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06757296 currently recruiting?
Yes, NCT06757296 is actively recruiting participants. Contact the research team at lim.chin.hong@singhealth.com.sg for enrollment information.
Where is the NCT06757296 trial being conducted?
This trial is being conducted at Singapore, Singapore, Singapore, Singapore, Singapore, Singapore.
Who is sponsoring the NCT06757296 clinical trial?
NCT06757296 is sponsored by Singapore Health Services. The principal investigator is Chin Hong Lim, MD at Singapore General Hospital. The trial plans to enroll 500 participants.